Eucommia Bark for Health & Longevity - Quick Reference Sheet
evipedia.ai
← Back

Eucommia Bark for Health & Longevity

Created on 08/25/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

An ancient Chinese bark tonic with rich chemistry and a thin human record. Vessel relaxation, bone-cell effects and gut bacterial shifts appear in animals; one short controlled trial lowered blood pressure only at the higher dose. Inexpensive and easy to monitor, plausibly useful just above optimal pressure, but animal kidney strain and hormone signalling stay unresolved. (Full Review)

Protocol

Standardised extract protocol
1 g, three times daily
Aqueous bark extract standardised to 8% pinoresinol diglucoside. The same extract at 500 mg three times daily produced no effect.
Traditional decoction protocol
6–15 g dried bark daily
Simmered as a decoction, usually salt-fried and usually inside a multi-herb formula rather than alone.
Best time of day
Divided, with meals
Morning and midday dosing suits the blood-pressure aim; a late-evening third dose is usually moved earlier.
Time to effect
Blood pressure
2 weeks
Changed within two weeks at the effective dose in the only controlled trial.
Bone endpoints
6–12 months
By analogy with every other bone agent; never measured in people.
Adiposity and lipids
4 weeks or longer
Holds where rodent dosing ran four weeks or longer; no outcome figure in people.

Benefits

Contraindications
  • Pregnancy and lactation at any stage
  • Hormone-sensitive cancers (oestrogen-receptor-positive breast, endometrial) or oestrogen-blocking therapy (aromatase inhibitors, tamoxifen)
  • Chronic kidney disease stage 3b or worse (estimated glomerular filtration rate under 45 mL/min/1.73 m2)
  • Symptomatic hypotension, or untreated resting systolic pressure below 100 mmHg
  • Within two weeks of elective surgery
  • Known hypersensitivity to Eucommia ulmoides or the finished preparation
    •
Key Interactions
  • Antihypertensive drugs (medicines that lower blood pressure): additive lowering risks symptomatic hypotension (lisinopril, losartan, amlodipine)
  • Diuretics (drugs that increase urine output): raises orthostatic hypotension risk (furosemide, hydrochlorothiazide)
  • Anticoagulants and antiplatelets (blood thinners): theoretical bruising or bleeding (warfarin, apixaban, clopidogrel)
  • Glucose-lowering drugs: possible additive glucose lowering (metformin, sulfonylureas, insulin)
  • Over-the-counter medications: decongestants oppose the effect (pseudoephedrine); non-steroidal anti-inflammatory painkillers raise pressure and renal strain (ibuprofen, naproxen)
  • Blood-pressure-lowering supplements: additive hypotension risk (beetroot nitrate, hibiscus, garlic extract, magnesium, taurine)
  • Bleeding-risk supplements: extended bleeding time (gram-dose fish oil, ginkgo, high-dose vitamin E)
  • Other interventions: acute pressure lowering (sauna, hot yoga, extended fasting, post-exercise vasodilation)

Risk & Side Effects

  • Medium: Excessive blood pressure lowering
    •
  • Low: Dose-dependent kidney injury; symptomatic adverse events; oestrogen receptor activation
  • Speculative: Additive bleeding risk; additive glucose lowering; contaminant and substitution exposure

Monitoring

Marker Target Why
Home blood pressure 110–120 / 70–75 mmHg The only endpoint with human trial support
Standing systolic drop Under 10 mmHg from seated Detects excessive vasodilation before fainting
Estimated glomerular filtration rate Above 90 mL/min/1.73 m2 Tracks the rodent renal toxicity signal
Serum creatinine 0.7–1.0 mg/dL for men, 0.6–0.9 for women Direct input to filtration estimates
Urine albumin-to-creatinine ratio Under 10 mg/g Earliest signal of kidney filter damage
High-sensitivity C-reactive protein Under 1.0 mg/L The claimed anti-inflammatory target
Fasting glucose and HbA1c 75–90 mg/dL; HbA1c 4.8–5.4% Detects additive glucose lowering
Bone mineral density T-score Above −1.0 The bone claim's only hard endpoint
CTX and P1NP Lower half of the reference range for CTX; no established target for P1NP, so track change from the individual's own baseline Move within months, unlike density

Cadence: Home blood pressure daily for two weeks, then twice weekly; kidney markers and glucose at three months, then every six to twelve months; lipids and inflammation at six months; bone density and turnover markers no sooner than twelve months apart.

Qualitative Assessment

  • Light-headedness on standing, especially in the first two weeks and in hot weather
  • Lower-back and knee comfort, the bark's oldest traditional indication
  • Perceived stamina and daytime fatigue
  • Sleep continuity and whether morning readings drift low
  • Any unusual bruising or prolonged bleeding from minor cuts
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.